China’s Helicobacter Pylori Vaccine Completes Phase III Clinical Trials
This article was originally published in PharmAsia News
Executive Summary
According to China's Ministry of Science and Technology, the Third Military Medical University of the PLA has successfully developed an oral recombinant Helicobacter pylori vaccine. The world's first such vaccine, the product has completed Phase III clinical trials and obtained the country's new drug certification. Trial results showed the vaccine to be effective and safe, with a protection rate of 72 percent in preventing H. pylori infection. The bacteria, which afflict some 50 percent of people in developing countries, cause gastric ulcers and show close correlation with stomach cancer. The developer of the vaccine, along with investors, are working hard to bring it to market as soon as possible. (Click here for more - Chinese Language)
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.